Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $48

Benzinga · 3d ago
Guggenheim analyst Yatin Suneja maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $46 to $48.